1. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections
- Author
-
Dorothy McCoy, Jon Hiles, Madeline King, Vanthida Huang, Nicole Harrington, Tiffany E. Bias, Lynette Richards, Safia Kuriakose, Julianne Gardner, Claudine El-Beyrouty, Jason C. Gallagher, Kenneth Biason, and Emily L. Heil
- Subjects
0301 basic medicine ,medicine.medical_specialty ,030106 microbiology ,Population ,Microbial Sensitivity Tests ,Carbapenem-resistant enterobacteriaceae ,Clinical Therapeutics ,Ceftazidime ,03 medical and health sciences ,Antibiotic resistance ,Enterobacteriaceae ,Drug Resistance, Multiple, Bacterial ,Chart review ,medicine ,Humans ,Pharmacology (medical) ,In patient ,Hospital Mortality ,Intensive care medicine ,education ,Retrospective Studies ,Pharmacology ,education.field_of_study ,biology ,business.industry ,Enterobacteriaceae Infections ,Ceftazidime/avibactam ,biology.organism_classification ,Anti-Bacterial Agents ,Cephalosporins ,Drug Combinations ,Carbapenem-Resistant Enterobacteriaceae ,Infectious Diseases ,Carbapenems ,Multicenter study ,beta-Lactamase Inhibitors ,business ,Azabicyclo Compounds ,medicine.drug - Abstract
Ceftazidime-avibactam is a novel cephalosporin–beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe a retrospective chart review for 60 patients who received ceftazidime-avibactam for a CRE infection. In-hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.
- Published
- 2017
- Full Text
- View/download PDF